Does Jardiance Lower Blood Pressure?
Jardiance (empagliflozin), an SGLT2 inhibitor for type 2 diabetes, reduces systolic blood pressure by 3-5 mmHg on average in clinical trials, mainly through its diuretic effect that promotes sodium and water excretion.[1][2] This drop is usually beneficial for patients with hypertension but can lead to excessive lowering in some cases.
When Can It Lower Blood Pressure Too Much?
Hypotension occurs in about 0.5-1% of patients, more often in those with low baseline blood pressure, on diuretics, or with volume depletion from illness.[3] Trials like EMPA-REG OUTCOME showed higher rates in elderly patients or those with heart failure.[1] Symptoms include dizziness, fainting, or fatigue.
Who Is at Higher Risk?
- Patients on loop diuretics (e.g., furosemide) or other antihypertensives, as Jardiance amplifies volume loss.
- Older adults, dehydrated individuals, or those with kidney impairment (eGFR <45 mL/min).
- People starting at low BP (<110/70 mmHg).[2][4]
Monitor BP closely at initiation and adjust other meds if needed.
How to Manage Excessive Drops
Doctors recommend:
- Hydration and electrolyte checks.
- Dose reduction or pausing if symptomatic.
- Temporary hold during acute illness (e.g., vomiting).[3]
No specific reversal agent exists; recovery follows fluid replacement.
Comparison to Other SGLT2 Inhibitors
Jardiance's BP effect matches Invokana (canagliflozin) and Farxiga (dapagliflozin), with similar hypotension rates (0.4-1.2%).[2] Metformin or GLP-1s like Ozempic cause less BP change.
Clinical Evidence from Key Trials
| Trial | BP Reduction | Hypotension Incidence |
|-------|--------------|-----------------------|
| EMPA-REG OUTCOME | -4.3/-1.6 mmHg | 0.6% (vs 0.4% placebo) [1] |
| EMPEROR-Reduced | -3.7 mmHg systolic | 1.3% [4] |
Real-world data confirms low but consistent risk.[3]
[1]: NEJM - EMPA-REG OUTCOME
[2]: FDA Label - Jardiance
[3]: Drugs.com - Jardiance Side Effects
[4]: NEJM - EMPEROR-Reduced